IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC

被引：2
|
作者：
Wang, Jie
Fan, Yun
Fang, Jian
He, Jianxing
Liu, Yunpeng
Tao, Min
Altorki, Nasser
Felip, Enriqueta
Wakelee, Heather
Vallieres, Eric
Belleli, Rossella
McNally, Virginia
Bennett, Elizabeth
Gitlitz, Barbara J.
Zhou, Caicun
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT239
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR plus NSCLC.
    Yue, Dongsheng
    Xu, Shi-Dong
    Wang, Qun
    Li, Xiaofei
    Shen, Yi
    Zhao, Heng
    Chen, Chun
    Mao, Weimin
    Liu, Wei
    Liu, Junfeng
    Zhang, Lan-Jun
    Ma, Haitao
    Li, Qiang
    Yang, Yue
    Liu, Yongyu
    Chen, Haiquan
    Zhang, Zhenfa
    Zhang, Bin
    Gong, Fuyu
    Wang, Changli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] MAGE-A3 GENE EXPRESSION FREQUENCY AND DEMOGRAPHY DATA OF STAGE IB-IIIA NSCLC PATIENTS FROM ONGOING MAGRIT PHASE III TRIAL EVALUATING MAGE-A3 ANTIGEN SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT TREATMENT
    Kim, J. H.
    Jassem, J.
    Tada, H.
    Yoshimura, M.
    Piantedosi, F.
    Zatloukal, P.
    Krakorova, G.
    Debois, M.
    Debruyne, C.
    Vansteenkiste, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 134 - 134
  • [43] Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
    Wu, Yi-Long
    Lu, Shun
    Yang, James Chih-Hsin
    Zhou, Jianying
    Seto, Takashi
    Ahn, Myung-Ju
    Su, Wu-Chou
    Yamamoto, Noboru
    Kim, Dong-Wan
    Paolini, Jolanda
    Usari, Tiziana
    Iadeluca, Laura
    Wilner, Keith D.
    Goto, Koichi
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (10):
  • [44] Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
    Yopp, A.
    Kudo, M.
    Chen, M.
    Cheng, A-L.
    Kaseb, A. O.
    Lee, H. C.
    Qin, S.
    Cha, E.
    Hack, S. P.
    Lian, Q.
    Spahn, J.
    Wu, C.
    Chow, P.
    ANNALS OF ONCOLOGY, 2024, 35 : 1230 - 1230
  • [45] IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
    Bex, A.
    Uzzo, R.
    Karam, J. A.
    Master, V. A.
    Donskov, F.
    Suarez, C.
    Albiges, L.
    Rini, B. I.
    Tomita, Y.
    Kann, A.
    Procopio, G.
    Massari, F.
    Zibelman, M.
    Antonyan, I.
    Huseni, M.
    Basu, D.
    Ci, B.
    Leung, W.
    Khan, O.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1431 - S1432
  • [46] Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care
    Asmis, T. R.
    Powell, E.
    Karapetis, C. S.
    Jonker, D. J.
    Tu, D.
    Jeffery, M.
    Pavlakis, N.
    Gibbs, P.
    Zhu, L.
    Dueck, D. -A.
    Whittom, R.
    Langer, C.
    O'Callaghan, C. J.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 118 - 126
  • [47] Comorbidity and overall survival (OS) in cetuximab-treated patients with advanced colorectal cancer (ACRC)-Results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care (BSC)
    Powell, E. D.
    Asmis, T.
    Jonker, D.
    Tu, D.
    Karapetis, C.
    Jeffery, M.
    O'Callaghan, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, P.
    Finn, R. S.
    Qin, S.
    Ikeda, M.
    Ducreux, M.
    Kim, T. -Y
    Lim, H. Y.
    Kudo, M.
    Breder, V
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Shao, H.
    Liu, J.
    Li, L.
    Zhu, A. X.
    Cheng, A. -L
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 34 - 34
  • [49] Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study
    Van der Heijden, M. S.
    Loriot, Y.
    Duran, I.
    Ravaud, A.
    Retz, M. M.
    Vogelzang, N. J.
    Nelson, B.
    Wang, J.
    Shen, X.
    Powles, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).
    O'Brien, Mary E. R.
    Kelly, Karen
    Altorki, Nasser K.
    Eberhardt, Wilfried Ernst Erich
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Kim, Joo-Hang
    Cho, Eun Kyung
    Hoffman, Philip C.
    Keshavjee, Shaf
    Orlov, Sergey
    Serwatowski, Piotr
    Wang, Joe
    Foley, Margaret A.
    Horan, Julie D.
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345